MedImmune FluMist price halved
Executive Summary
MedImmune is cutting the price of the intranasal influenza vaccine FluMist to $23.50 per dose from the $46 price tag used during the 2003-2004 season. The company previously indicated that a price reduction for FluMist was under consideration following weak sales of the vaccine in its first year on the market (1"The Pink Sheet" April 26, 2004, p. 43). FluMist posted sales of $77 mil. during the 2003-2004 flu season...
You may also be interested in...
FluMist Price Likely To Be Cut To $20-$25 Per Dose, MedImmune Says
MedImmune is considering reducing the price for the intranasal flu vaccine FluMist to $20-$25 per dose for the 2004-2005 season, CEO David Mott indicated during a first quarter conference call April 21
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.